EXECUTIVE BOARD

SUMMARY

116th Meeting Executive Board

Minutes

Members:  Dr. G Beastall (GB) President
          Prof. J Hicks (JH) Past President
          Prof. H Morris (HM) Vice President
          Dr. B Gouget (BG) Treasurer
          Prof. S Bernardini (SB) Secretary
          Prof. L Kricka (LK) Member
          Prof V Steenkamp (VS) Member
          Dr. U Tuma (UT) Member
          Dr. T Brinkmann (TB) Corporate Rep

In attendance: Ms P Bramati (PB) IFCC Office
Strategic Plan for the IFCC Executive Board for the three year period 2012-2014.

Twenty six strategic actions have been identified and classified into the following four broad areas:

A. Supporting our membership
B. Broadening our horizons
C. Improving the quality of laboratory medicine
D. Improving the effectiveness of IFCC

It is intended that the plan may be modified in the light of changing circumstances. The Strategic Plan is intended to complement the planning and action of IFCC Divisions, Committees and Working Groups. Some of the identified priorities overlap with the work of Divisions and dialogue is required to agree a co-ordinated approach.

### Area A: Supporting our Membership

<table>
<thead>
<tr>
<th>Number</th>
<th>Strategic Action</th>
</tr>
</thead>
</table>
| 1      | a) Introduce electronic voting for elections to the Executive Board  
        b) Conduct a ‘mock election’ to let Members gain experience of electronic voting |
| 2      | Introduce the support mechanisms to maximise the potential of Survey Monkey |
| 3      | a) Conduct three surveys of Members opinion each year, one of which should relate to identifying the ways in which IFCC can best support its members.  
        b) Evaluate results and implement actions |
| 4      | a) Develop new support materials and web-based tools to demonstrate the benefits of IFCC membership to developing countries  
        b) Use and evaluate effectiveness of new support materials |
| 5      | a) Identify ways to improve the two-way communication between IFCC and Members  
        b) Implement and evaluate methods to improve communication with Members |
| 6      | Establish and promote a register of expertise amongst individuals in IFCC that may be of value to Members, especially in developing countries |
| 7      | Facilitate the development, production and promotion of at least three new projects in distance learning that will be of benefit to Members |
| 8      | Develop and promote materials to assist Members to promote the contribution of laboratory medicine to healthcare in their Country |
| 9      | Organise at least one opportunity each year for the Executive Board to meet with the Presidents of each of the IFCC Regional Federations to identify opportunities for collaboration |
| 10     | a) Improve communication with COLABIOCLI and with Members in Latin America  
        b) Support at least one major new project in the Region  
        c) Conclude a formal agreement between IFCC and COLABIOCLI |

### Area B: Broadening Our Horizons

<table>
<thead>
<tr>
<th>Number</th>
<th>Strategic Action</th>
</tr>
</thead>
</table>
| 11     | a) Agree a change in Statutes that will open up Full Membership of IFCC  
        b) Agree and present a strategy to demonstrate benefits of expanded Full Membership  
        c) Present the new Statutes to Council for voting |
| 12     | a) Develop a strategy and new materials for expanding Corporate Membership of IFCC, to include the private and academic sectors; and health informatics companies  
        b) Undertake targeted campaigns to expand Corporate Membership |
| 13     | Identify, resource, prepare and deliver one new project each year in areas of laboratory medicine other than clinical chemistry |
| 14     | a) Develop a plan to increase collaboration between IFCC and international clinical organisations  
        b) Establish at least one new collaboration each year with an international clinical organisation |
<table>
<thead>
<tr>
<th>Number</th>
<th>Strategic Action</th>
</tr>
</thead>
</table>
| 15     | a) Agree a work programme for the new Task Force on the Impact of Laboratory Medicine on Clinical Management and Outcomes (TF-ICO)  
         b) Identify and support at least one new project each year for TF-ICO |
| 16     | a) Agree a work programme for the new Task Force on Point of Care Testing (TF-POCT)  
         b) Identify and support at least one new project each year for TF-POCT |
| 17     | a) Ensure succession planning in the Task Force for Young Scientists (TF-YS)  
         b) Develop and deliver a plan to encourage more involvement of Young Scientists in their national societies and in IFCC activities |

**Area C: Improving the Quality of Laboratory Medicine**

<table>
<thead>
<tr>
<th>Number</th>
<th>Strategic Action</th>
</tr>
</thead>
</table>
| 18     | a) In conjunction with others develop a route to laboratory accreditation for developing countries  
         b) Apply the resource material at least once per year and evaluate its effectiveness |
| 19     | Position the IFCC in relation to the future organisation and delivery of the AACC-led method harmonisation project |
| 20     | Establish at least one new project with WASPaLM that aims to improve the quality of laboratory medicine through global harmonisation |
| 21     | Establish at least one new project with ILAC that aims to improve the application of quality management and laboratory accreditation |
| 22     | a) Strengthen links and collaboration with WHO  
         b) Develop a project that summarises and promotes the value of laboratory medicine in the elderly and in chronic disease - in line with the WHO priority area |

**Area D: Improving the Effectiveness of IFCC**

<table>
<thead>
<tr>
<th>Number</th>
<th>Strategic Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>Review IFCC finances and identify opportunities to improve financial performance. Identify opportunities for at least one new income stream</td>
</tr>
</tbody>
</table>
| 24     | a) Benchmark the structure, organisation and performance of IFCC against other established Federations that are active in science and/or medicine  
         b) Prepare and implement a report on how the information gained from other Federations can help to improve the efficiency of IFCC |
| 25     | a) Agree a process for auditing the performance of IFCC in meeting the needs of Members and in representing the interests of global clinical chemistry and laboratory medicine  
         b) Audit the performance of IFCC against targets and suggest actions for the next Strategic Plan |
| 26     | a) Undertake and publish an horizon scanning project to assess how laboratory medicine will be organised and delivered in 2020 and beyond  
         b) Make recommendations for IFCC in order to help it position itself in the changing world of laboratory medicine |
2. Full Member Societies

2.2 Applications for Full Membership: Zimbabwe was accepted as full member being approved by the majority.

3. Corporate Members

Six IVD companies joined IFCC as Corporate Members: Immunodiagnostics Systems (UK), LabQuality (Finland), Nova Biomedical Corporation (France), Response Biomedical Corporation (Canada), Shenzhen Mindray Bio-Medical Electronics (China), Unilabs (Switzerland). Due to the acquisition of Phadia by ThermoFischer one member was lost.

5. Regional Organisations

5.1 Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine (APFCB).
The Federation name change to Asia Pacific Federation for Clinical Biochemistry and Laboratory Medicine, without changing the abbreviation APFCB. Howard Morris has been confirmed as APFCB liaison on the Executive Board.

5.4 European Federation of Clinical Chemistry and Laboratory Medicine (EFCC)
EB noted that the Federation abbreviation is likely to change to EFLM. Sergio Bernardini, was confirmed as EFCC liaison on the Executive Board.

5.6 Arab Federation of Clinical Biology (AFCB)
Bernard Gouget has been confirmed as AFCB liaison on the Executive Board.

7. Committee on Congresses and Conferences (C-CC)

7.3.2.21 EuroMedLab Paris 2015
BG reported that the EuroMedLab Paris 2015 congress will incorporate the Journées Internationales de Biologie (JIB) 2015 congress in the scientific programme and exhibition.

7.4 IFCC Specialised Conferences
7.4.1 Roche Bergmeyer Conference, 5-7 March 2012, Eibsee, Germany
The arrangements for this conference on Vitamin D are complete.

7.8 Congresses with IFCC Auspices
The list of congresses awarded IFCC auspices is updated and published on the IFCC website.

7.20 Membership
EB confirmed Peng Yin of Abbott Diagnostics Division as Corporate Member to C-CC and Mauri Keinanen of LabQuality as a Corresponding Member of C-CC

8. Scientific Division (SD)

8.2 SD Committees
8.2.6 C-Nomenclature, Properties and Units (C-NPU)
Robert Flatman (AU) has been appointed as the new Chair of C-NPU (and endorsed by IUPAC).

8.3 SD Working Groups
8.3.50 WG –Standardisation of Bone Marker Assays
Membership has been agreed with nominations from IFCC, International Osteoporosis Foundation and Corporate Members Roche Diagnostics and IDS. The Chair of WG has been invited to address the IOF Congress in Rome 2013. The scientific project will commence in March 2012.

8.16 AACC Harmonisation Project
EB agreed that this Project is numbered 8.16. The project aims to create a structure and process to enable method harmonisation in situations where full traceability (standardisation) may not be possible. The project is led by AACC but there are a number of links to IFCC.

8.20 Membership
EB agreed that Christa Cobbaert (NL) will replace Lothar Siekmann, in SD-EC.

9. Education and Management Division (EMD)

9.4.1 Visiting Lecturer Programme (coordinated by Leslie Lai)
Applications for 2012 include: Chile (Mario Plebani), Cuba (GB, BG), Palestine (Sverre Sandberg, BG).

9.20 Membership
Elizabeth Frank (India) has been appointed to the EMD Executive Committee. As Elizabeth is currently an EMD Committee Chair the EMD will seek to appoint a new chair to the Committee for Clinical Laboratory Management and advertise the vacancy.

10. Communications and Publications Committee (CPD)

10.7 Website
The CPD continues to update the website in response to feedback received.

10.4 Other business
- The Task Force on the Value of Laboratory Medicine EB approved the change of name to “TF on the Impact of Laboratory Medicine on Clinical Management and Outcomes” (TF-ICO) and adopt the number 13.01.09. Mike Hallworth (UK) has accepted the invitation to Chair this Task Force and has been approved by EB.

- Historical Presentation. The CPD Executive will prepare a historical Power Point presentation in support of the IFCC 60th anniversary at the General Conference in Kuala Lumpur.

13 Special Projects and Task Forces

The TF have been renumbered according with the following list:
13.01 Task Forces
13.01.01 Task Force on Ethics (TF-Ethics)
13.01.02 Task Force on Paediatric Laboratory Medicine (TF-PLM)
13.01.03 Task Force on Pharmacogenetics (TF-PG) (Integrated Project)
13.01.04 Task Force on Chronic Kidney Disease (TF-CKD) (Integrated Project)
13.01.05 Task Force on Reporting HbA1c (TF-HbA1c) (Integrated Project)
13.01.06 Task Force on International Clinical Liaison (TF-ICL)
13.01.07 Task Force for Young Scientists (TF-YS)
13.01.08 Task Force on POCT (TF-POCT) (Integrated Project)
13.01.09 Task Force on the Impact of Laboratory Medicine on Clinical Management and Outcomes (TF-ICO) (Integrated Project)
13.02 Professional Exchange Programmes
  13.02.01 Professional Scientific Exchange Programme (PSEP)
  13.02.02 Professional Management Exchange Programme (PMEP)

13.03 Roche Travel Scholarships

13.01.01 Task Force on Ethics (TF-E)
The “conflict of interest and disclosure statement” presented to the previous meeting of the EB has been reconsidered and a final simplified version has been produced. EB suggested that all current EB and Division EC members lead by example and complete disclosure. Thereafter, completion of the disclosure statement (by electronic means) should occur whenever someone joins an IFCC Division, Committee or Task force or is appointed as a WG Chair.

13.01.02 Task Force on Paediatric Laboratory Medicine (TF-PLM)
EB noted the revised membership of the Task Force:

- V. L. Grey  Chair  CA  1st  2012 01 - 2014 12
- M. Metz  Vice Chair  AU  1st  2012 01 - 2014 12
- S. M. Geaghan  Member  US  1st  2011 01 - 2013 12
- P. M. Jones  Member  US  2nd  2012 01 - 2014 12
- T. Lang  Member  GB  1st  2012 01 - 2014 12
- K. Kohse  Consultant  DE  1st  2012 01 - 2014 12

V.L. Gray will send a call for nomination for the Scientific Advisory Board of the XIII ICPLM in Istanbul in 2014.

13.01.03 Task Force on Chronic Kidney Disease (TF-CKD) joint with WASPaLM
Graham Jones will continue as Chair of this Task Force.

13.01.08 Task Force on POCT
The call for nomination for Chair and for Members of TF-POCT was closed on February 17th.
The CV evaluation of 2 candidates for Chair, 8 candidates for members nominated by Societies and 3 candidates nominated by Corporates is ongoing.

13.03 Roche Travel Scholarships
An invitation to bid for Roche Travel Scholarships has been sent to all NSs that are Full or Affiliate Members of IFCC in Low and Lower Middle Income countries. The Roche Travel Scholarship scheme has been extended to IFCC National Representatives from selected countries in order to facilitate attendance at the IFCC General Conference.

16.0 Organisational Matters

16.2 Awards Committee
EB considered the membership of the IFCC Awards Committee for 2012-2014

16.3 Nominations Committee
EB considered the composition of the IFCC Nominations Committee for 2012-2014

19.0 Meetings

19.6 General Conference
The General Conference will be held on November 18-19, 2012 in Kuala Lumpur.